CAJ | 학술논문

目的：研究胃癌不同的ERCC1和p53表达状态及对基于顺铂为主的辅助化疗患者无病生存期（ DFS）和总生存期（ OS）的影响。方法收集48例胃癌根治术后患者的临床及病理资料，应用免疫组织化学方法检测ERCC1和p53在胃癌组织中的表达，采用SPSS17．0软件进行统计学分析，χ2检验分析两种因子表达与临床特征的相关性，Kaplan－Meier方法分析两种因子表达对含铂类辅助化疗患者生存期的影响。结果 ERCC1， p53的表达与肿瘤发病部位、大小、浸润深度、组织学类型、淋巴结转移、TNM分期无关。 ERCC1表达阳性者DFS 11．5个月，中位OS 20个月，ERCC1阴性表达者DFS 14．5个月，中位OS为23个月；p53表达阳性者DFS 10个月，中位OS 18个月，p53表达阴性者DFS 12个月，中位OS为22个月。 ERCC1阳性表达患者与阴性表达患者比较，DFS差异无显著性（P＞0．05），中位OS差异有显著性（P＜0．05），p53阳性表达患者与阴性表达患者比较， DFS和中位OS差异均无显著性（P＞0．05）。结论胃癌ERCC1和p53的表达与临床特征不相关，ERCC1可以作为胃癌根治术后接受含铂类辅助化疗疗效的预测指标，p53的表达状态可能不是该类方案的疗效预测因子。
목적：연구위암불동적ERCC1화p53표체상태급대기우순박위주적보조화료환자무병생존기（ DFS）화총생존기（ OS）적영향。방법수집48례위암근치술후환자적림상급병리자료，응용면역조직화학방법검측ERCC1화p53재위암조직중적표체，채용SPSS17．0연건진행통계학분석，χ2검험분석량충인자표체여림상특정적상관성，Kaplan－Meier방법분석량충인자표체대함박류보조화료환자생존기적영향。결과 ERCC1， p53적표체여종류발병부위、대소、침윤심도、조직학류형、림파결전이、TNM분기무관。 ERCC1표체양성자DFS 11．5개월，중위OS 20개월，ERCC1음성표체자DFS 14．5개월，중위OS위23개월；p53표체양성자DFS 10개월，중위OS 18개월，p53표체음성자DFS 12개월，중위OS위22개월。 ERCC1양성표체환자여음성표체환자비교，DFS차이무현저성（P＞0．05），중위OS차이유현저성（P＜0．05），p53양성표체환자여음성표체환자비교， DFS화중위OS차이균무현저성（P＞0．05）。결론위암ERCC1화p53적표체여림상특정불상관，ERCC1가이작위위암근치술후접수함박류보조화료료효적예측지표，p53적표체상태가능불시해류방안적료효예측인자。
[ ABSTRACT] Objective To study the expression of ERCC 1 and p53 in gastric cancer of different state and its effect on patients with disease free survival ( DFS) and overall survival ( OS) based on cisplatin based adjuvant chemo-therapy .Methods Postoperative clinical and pathological data of forty-eight patients with gastric cancer were collected , immunohistochemical method was used to detect the expression of ERCC 1 and p53 in gastric carcinoma tissues ,statistical analysis was made by SPSS17.0 software,the correlation between the expression and clinical features of two factors were analyzed by chi-square test ,and Kaplan-Meier analysis was used to analyze the effect of platinum adjuvant chemotherapy on patients'survival .Results The expression of ERCC 1 and p53 were not correlated to features of the primary tumor such as tumor onset location,size,depth of invasion,histological type,lymph node metastasis and TNM stage .The with positive expression of ERCC 1 was 11 .5 months and 20 months .The negative expression of ERCC 1 was 14 .5 months and 23 months.The DFS and median OS of patients with positive or negative expression of p 53 was 10 months,18 months,12months and 22 month respectly .The positive expression of ERCC 1 in patients with negative expression patients were com-pared,no significant difference(P>0.05) was found in DFS but significant differences were found in median OS (P<0. 05 ) .In the positive expression of p 53 in patients with negative expression patients'comparison , DFS and median OS showed no significant difference (P>0.05).Conclusion The expression of ERCC1 and p53 does not correlate with the clinical features in gastric cancer ,ERCC1 can be used as a predictive index after radical operation of gastric carcinoma received platinum containing adjuvant chemotherapy and p 53 may not be predictors of the efficacy of cisplatin .